APT, Atreus Site-Specifically Label Annexin V, Developing In Vivo Imaging Biomarker | GenomeWeb

Advanced Proteome Therapeutics and Atreus Pharmaceuticals have successfully site-specifically modified annexin V using a proprietary chemical approach, APT said this week.

As a result, various chemical entities can now be attached to the protein and thus enable the development of commercial products. The first such product currently under development is a conjugate of 1,4,7-traizacyclononane-1,4,7-triacetic acid, or NOTA, and recombinant human annexin V.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.